Uppsala, Sweden, November 27th, 2009
Beactica, the Swedish fragment-based drug discovery company, today announced its participation in a Marie Curie Initial Training Network (ITN). The ITN, called BrainTrain, is funded through the 7th EU Framework Programme and aims to deliver 15 skilled early stage researchers in the field of neuroscience.
The network is composed of eight leading EU institutes (Amsterdam, London, Paris, Heidelberg, Stockholm, Magdeburg, Leuven and Trieste) together with Japanese RIKEN and five commercial partners. Beactica’s contribution will include the training of several young investigators in the science of surface plasmon resonance (SPR)-based molecular interaction analysis. The candidates will be applying Beactica’s state-of-the-art discovery platform for the study of synaptic protein–protein interactions.
"Participating in the ITN BrainTrain enables Beactica to contribute towards research in one of the most pressing and costly problems of society. It also enables the company to further develop its basic research in the CNS area.” said Prof. Helena Danielson, CSO, Beactica.
With the start of BrainTrain, Beactica initiates its second EU-funded project that focuses on fundamental brain research. The ongoing NeuroCypres project targets a family of proteins known as the Cys-loop receptors with crucial functions in the peripheral and central nervous system. BrainTrain will use genomic information and exploit innovative approaches to unravel the function and dysfunction of synaptic molecular recognition events. The official webpage of BrainTrain is www.brain-train.nl.
For additional information please contact Dr Per Källblad, Beactica CEO, +46 18 56 08 80.
Sign up for the Beactica newsletter to receive our latest news and updates